New Two-Drug attack targets Hard-to-Treat advanced cancers
NCT ID NCT07446049
First seen Mar 05, 2026 · Last updated Apr 09, 2026 · Updated 5 times
Summary
This study is testing a new combination of an oral tablet (CVL237) and an immunotherapy injection (serplulimab) for people with advanced solid tumors that have a specific genetic feature called PTEN loss or low expression. The main goals are to find the safest and most effective dose and to see how well the combination controls cancer growth and extends the time before the disease gets worse. It is for adults with certain advanced cancers who have already tried standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.